학술논문
Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience.
Document Type
Academic Journal
Author
Bardazzi F; Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy.; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna.; Viviani F; Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy.; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna.; Merli Y; Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy.; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna.; Di Lernia V; Dermatology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.; Peccerillo F; Dermatology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.; Conti A; Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy.; Lasagni C; Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy.; Tabanelli M; Dermatology Unit, AUSL della Romagna, Ravenna, Italy.; D'Adamio S; Dermatology Unit, AUSL della Romagna, Ravenna, Italy.; Di Nuzzo S; Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy.; Cortellazzi C; Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy.; Filippi F; Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy.; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna.
Source
Publisher: Taylor & Francis Country of Publication: England NLM ID: 101125414 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7682 (Electronic) Linking ISSN: 14712598 NLM ISO Abbreviation: Expert Opin Biol Ther Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Real-world data for guselkumab, the first interleukin-23 inhibitor approved to treat moderate-to-severe psoriasis, are scarce. This study represents the first 60-week, real-life, multicenter, retrospective experience to investigate the effectiveness, safety, tolerability, and drug retention of guselkumab in psoriatic patients.
Research Design and Methods: Clinical information was collected at baseline and at weeks 12, 24, 36, 48, and 60.
Results: The mean baseline Psoriasis Activity Severity Index (PASI) reduced from 14.2 to 3.1 at week 12 and decreased to around 0 at weeks 36, 48, and 60. PASI 75, PASI 90, and PASI 100 were 100%, 96.8%, and 83.9% at week 60, respectively. Multiple logistic regression analysis showed that neither body mass index >30, smoking, ≥3 comorbidities, difficult-to-treat areas, nor a failure to ≥2 prior biologic treatments significantly influenced PASI reduction (p > 0.05).
Conclusions: Our findings confirm guselkumab as an appropriate therapeutic option in routine clinical practice, especially when dealing with complex patients with comorbidities or previous failure to biologic treatments.
Research Design and Methods: Clinical information was collected at baseline and at weeks 12, 24, 36, 48, and 60.
Results: The mean baseline Psoriasis Activity Severity Index (PASI) reduced from 14.2 to 3.1 at week 12 and decreased to around 0 at weeks 36, 48, and 60. PASI 75, PASI 90, and PASI 100 were 100%, 96.8%, and 83.9% at week 60, respectively. Multiple logistic regression analysis showed that neither body mass index >30, smoking, ≥3 comorbidities, difficult-to-treat areas, nor a failure to ≥2 prior biologic treatments significantly influenced PASI reduction (p > 0.05).
Conclusions: Our findings confirm guselkumab as an appropriate therapeutic option in routine clinical practice, especially when dealing with complex patients with comorbidities or previous failure to biologic treatments.